Print
Email
Print Edition Stories
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Medical device titan Boston Scientific Corp. has pulled together two deals worth $3 billion combined in loans and credit to replace its existing $1.75 billion revolving credit facility and pay some upcoming notes.
According to officials at Natick-based Boston Scientific, the existing revolving credit facility is set to mature in April 2011. With the some of the remaining $1.25 billion, the company will immediately pay in full a $900 million term loan from Abbot Laboratories that is also due in April of 2011. In addition, Boston Scientific will add some of its own cash on hand to repay $850 million in senior notes, some of which will mature in January 2011 and the rest in June 2011.
The new $3 billion credit line is made up of a $1 billion, three-year term loan and a $2 billion, three-year revolving credit facility. The package comes from a syndicate, according to Boston Scientific, (NYSE:BSX) which did not disclose the entities involved.
Almost one month after getting approval from the European Union to sell its third-generation drug-eluting stent, the Taxus Element Paclitaxel-Eluting Coronary Stent System, Boston Scientific got its first patient receiving the implant.
The drug-eluting stent has yet to be approved in the U.S., but Boston Scientific officials have said that the company expects approval from the U.S. Food and Drug Administration in mid-2011.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
